Anti-Diabetes Drugs - Italy | Statista Market Forecast

The Anti-Diabetes Drugs market in Italy is projected to witness a significant revenue growth, with an estimated value of US$958.50m in 2024.
This indicates a positive trend in the market, highlighting the rising demand for anti-diabetes medications in the country.
Looking ahead, the market is expected to continue its growth trajectory, with an annual growth rate (CAGR 2024-2029) of 6.57%.
By 2029, it is anticipated that the market volume will reach US$1.32bn, further solidifying the prominence of the Anti-Diabetes Drugs market in Italy.
When compared globally, it is worth noting that United States is expected to generate the highest revenue in the Anti-Diabetes Drugs market, with a staggering value of US$37.84bn in 2024.
This showcases the dominant position of the United States in the global market, underscoring its strong healthcare industry and high prevalence of diabetes cases.
Italy has seen a rise in the demand for innovative anti-diabetes drugs, driven by an aging population and increasing awareness about diabetes management.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Italy has been experiencing significant growth in recent years.

Customer preferences: Italian consumers have been increasingly aware of the importance of managing diabetes. This has led to a rise in demand for anti-diabetes drugs, as more people seek to control their blood sugar levels. Additionally, the aging population in Italy has also contributed to the growth of the market, as older individuals are more likely to develop diabetes.

Trends in the market: One of the major trends in the Anti-Diabetes Drugs market in Italy is the shift towards newer, more innovative treatments. This includes the use of GLP-1 receptor agonists and SGLT-2 inhibitors, which have been shown to be more effective in managing blood sugar levels than traditional treatments. Additionally, there has been a growing trend towards personalized medicine, with doctors using genetic testing to identify the most effective treatment for individual patients.

Local special circumstances: Italy has a unique healthcare system, which has played a role in the development of the Anti-Diabetes Drugs market. The country has a universal healthcare system, which means that all citizens have access to healthcare services, including anti-diabetes drugs. Additionally, the Italian government has implemented a number of policies to promote the use of generic drugs, which has helped to keep prices low and increase access to treatment.

Underlying macroeconomic factors: The Italian economy has been struggling in recent years, with low growth and high levels of debt. This has had an impact on the Anti-Diabetes Drugs market, as consumers have become more price-sensitive and are looking for more affordable treatments. Additionally, the Italian government has been implementing a number of cost-saving measures in the healthcare sector, which has put pressure on drug manufacturers to reduce prices. Despite these challenges, the Anti-Diabetes Drugs market in Italy is expected to continue growing in the coming years, as the demand for effective treatments for diabetes remains high.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.